| Can we diagnose invasive cervical cancer during pregnancy as precise as in nonpregnant women?: maternal and perinatal outcome in pregnancies complicated with cervical cancers. | |
| | |
MedLine Citation:
|
PMID: 20009904 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Cervical cancer is the most common gynecologic malignancy associated with pregnancy. However, there are no consensus guidelines that define the indications for or the optimal length of expectant management. The subjects were women who had a preexisting invasive cervical cancer or whose cancers were diagnosed during pregnancy or within 12 months after delivery. Thirty-nine consecutive women with cervical cancer, whose ages ranged from 20 to 40 years, were chosen as controls. We performed a retrospective chart review on the maternal profile and perinatal outcome and compared the clinical features between pregnancy- and non-pregnancy-associated cervical cancer in patients. The percentage of asymptomatic cases in which cancer was detected in a routine Papanicolaou test was significantly higher in the pregnant patients. The percentage of induced preterm labor or therapeutic abortions was 50%. Expectant management (mean length, 19.8 weeks) was chosen by 5 patients, and there were no cases of recurrence or death from disease. Seven subjects, including 5 patients whose diagnoses were changed from cervical intraepithelial neoplasm or condyloma to cancer, were managed as "unexpected expectant" because these subjects were not diagnosed as having stage IA/IB cancer during pregnancy. All of these subjects underwent vaginal delivery and included 2 patients with death from disease and lymph node recurrence. The percentage in which disease severity was underestimated was higher in pregnant patients. The option of therapeutic delay should be carefully discussed. Patient counseling should address the issue that risk may not be precisely estimated because of the possibility that disease severity may be underestimated during pregnancy. |
| | |
Authors:
|
Kotaro Fukushima; Shinji Ogawa; Kiyomi Tsukimori; Hiroaki Kobayashi; Norio Wake |
Related Documents
:
|
16879994 - Up-regulation of the endothelin receptor a in placental tissue from first trimester del... 7659394 - Emergency cerclage: a review. 8423024 - Surgical management of early invasive cancer of the cervix associated with pregnancy. 18560344 - Preterm delivery and premature rupture of membranes after conization in 80 women. preli... 1354434 - Pregnancy in aplastic anemia treated with fetal liver and bone marrow hemopoietic cells... 11251614 - Adolescent girls and their babies: achieving optimal birthweight. gestational weight ga... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society Volume: 19 ISSN: 1525-1438 ISO Abbreviation: Int. J. Gynecol. Cancer Publication Date: 2009 Nov |
Date Detail:
|
Created Date: 2009-12-16 Completed Date: 2010-03-02 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9111626 Medline TA: Int J Gynecol Cancer Country: United States |
Other Details:
|
Languages: eng Pagination: 1439-45 Citation Subset: IM |
Affiliation:
|
Department of Obstetrics and Gynecology, Graduate School of Medical Sciences, Kyushu University, Higashi-ku, Fukuoka, Japan. kfuku@gynob.med.kyushu-u.ac.jp |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Cervical Intraepithelial Neoplasia / diagnosis*, therapy Delivery, Obstetric Female Humans Infant, Newborn Neoplasm Invasiveness Neoplasm Staging Obstetric Labor, Premature Perinatal Mortality* Pregnancy Pregnancy Complications, Neoplastic / diagnosis*, therapy Pregnancy Outcome* Prognosis Retrospective Studies Survival Rate Time Factors Uterine Cervical Neoplasms / diagnosis*, therapy Young Adult |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Preventing cervical cancer: stakeholder attitudes toward CareHPV-focused screening programs in Roi-e...
Next Document: Phase 2 trial of docetaxel, gemcitabine, and oxaliplatin combination chemotherapy in platinum- and p...